Clinical Trial

Outcomes of High-risk Non-muscle Invasive Bladder Cancer Treated With Blue Light Resection

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Comparing white-light cystoscopy (WLC) and blue-light cystoscopy (BLC) in TURBT for high risk (HR) non-muscle invasive bladder cancer (NMIBC) patients is crucial to determine the most effective method for reducing residual disease burden and improving recurrence-free survival. Enhanced visualization with BLC may lead to more accurate resections, potentially decreasing recurrence rates and improving long-term outcomes for bladder cancer patients. Patients will be randomized to either WLC TURBT or BLC TURBT, and outcomes will be measured using standard-of-care testing with cystoscopy and cytology, along with minimal residual disease (MRD) burden evaluation using urine next-generation sequencing.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-07-24; most recent amendment 2025-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-01-09
Trial Details
NCT Number NCT06525571
Lead Sponsor Johns Hopkins University
Collaborators: Photocure ASA
Conditions Bladder Cancer
Enrollment 200 participants
Start Date 2024-12-20
Primary Completion 2027-01-04 (estimated)
Study Completion 2028-01-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-18